glp 1 shortage update GLP-1 Deepens in Two States as Demand Remains High MCT2D | 2023 Updates to

Appetite suppression requires higher receptor occupancy than these doses provide

The reduction of cardiovascular events is not only related to anti-diabetic properties, but also to pleotropic effects leading to the reduction of the residual cardiovascular risk, that has been defined as the risk of progression of CV events (MACE or HF) that remains after the optimal glycaemic control in T2DM patients, and it seems to be related to meta-inflammation, defined as a low-grade chronic and sterile inflammatory status

Human Error & Handling Risks Common failures include leaving GLP-1 stock at room temperature during transfers or storing it in domestic fridges

Thereby, GLP-1 receptor agonists (GLP-1 RAs), which 1 ) correct six of the eight components of the Ominous Octet, 2 ) prevent/reverse the progressive -cell failure and rise in HbA 1c , and 3 ) lower cardiovascular risk in T2D independent of their glucose-lowering ability (9,10), should replace metformin as the recommended first-line therapy in newly diagnosed T2D patients

For more on the regulatory landscape affecting compounded GLP-1 access, Meto's breakdown of the 2026 FDA compounded peptide crackdown explains what has changed and what it means for patients

Data Availability Statement The datasets used during the current study are available from the corresponding author on reasonable request.